Phase I Open-Label Study of Omalizumab (Xolair) in Peanut-Allergic Patients
Kari C. Nadeau, MD, PhD Division of Allergy , Immunology, and Rheumatology at Stanford Describe the pathophysiology, initial evaluation & management of patients with food allergy including gastrointestinal food allergy, oral allergy syndrome and type I food allergy Identify recent advances in the field of food allergy and have some familiarity with published guidelines for managing food allergy Outline current and emerging treatment modalities for food allergic patients Nothing to disclose ID: 9.5 y.o. male with a history of severe food allergies, eczema, and asthma CC: Presents to PICU with hypoxic brain injury due to anaphylaxis from cow’s milk ingestion Transferred to PICU from outside hospital after multiple failed resuscitations over a 3 hr period On the evening of 8-11-04, patient accidentally drank from his sister’s cup of cow’s milk on the way to bed. He immediately developed emesis and became SOB; parents gave Epipen jr. to his thigh and called 911 Paramedics arrived in 10-15 minutes On the scene, intubation was attempted but difficult Duration of code=1 hr. CT scan showed hypoxic injury and right uncal herniation. In 2001, he presented to LPCH AAI clinic and had severe eczema and asthma. RAST tests were performed at 2001 and showed IgE > 2000, Milk> 100, Peanut>100, Egg 40.3, Soy 17.9, Wheat 20.2, Corn 26.3, Oat 12.3. No known allergies to beef. He had had one prior visit to the ER for milk ingestion in 2001. He presented with hyperventilation and emesis. He was given benadryl and his symptoms improved.
[Show full text]